Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: A modelling study based on longitudinal tumor measurements

View ORCID ProfileSarah C. Brüningk, Jeffrey Peacock, Christopher J. Whelan, Hsiang-Hsuan M. Yu, Solmaz Sahebjam, Heiko Enderling
doi: https://doi.org/10.1101/2021.01.09.21249317
Sarah C. Brüningk
1Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland
2Swiss Institute for Bioinformatics (SIB), Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah C. Brüningk
  • For correspondence: sarah.brueningk@bsse.ethz.ch
Jeffrey Peacock
3Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Whelan
4Department of Cancer Physiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsiang-Hsuan M. Yu
3Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
5Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solmaz Sahebjam
5Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
6Department of Neuro-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heiko Enderling
3Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
5Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
7Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Recurrent high grade glioma patients face a poor prognosis for which no curative treatment option currently exists. In contrast to prescribing high dose hypofractionated stereotactic radiotherapy (HFSRT, ≥ 6 Gyx5 in daily fractions) with debulking intent, we suggest a personalized treatment strategy to improve tumor control by delivering intermittent high dose treatment (iRT, ≥ 6 Gyx1 every six weeks). We performed a simulation analysis to compare HFSRT, iRT and iRT plus boost (≥ 6 Gyx3 in daily fractions at time of progression) based on a mathematical model of tumour growth, radiation response and patient-specific evolution of resistance to additional treatments (pembrolizumab and bevacizumab). Model parameters were fitted from tumour growth curves of 16 patients enrolled in the phase 1 NCT02313272 trial that combined HFSRT with bevacizumab and pembrolizumab. Then, iRT +/-boost treatments were simulated and compared to HFSRT based on time to tumor regrowth. The modelling results demonstrated that iRT+boost(-boost) treatment was equal or superior to HFSRT in 15(11) out of 16 cases and that patients that remained responsive to pembrolizumab and bevacizumab would benefit most from iRT. Time to progression could be prolonged through the application of additional, intermittently delivered fractions. iRT hence provides a promising treatment option for recurrent high grade glioma patients.

Competing Interest Statement

SS receives research support from Merck, Bristol Myers Squibb, and Brooklyn ImmunoTherapeutics and acts as advisory board member for Merck, and Boehringer Ingelheim. HY is on the advisory board of AbbVie and Novocure and is a member of the speaker bureau of BrainLab. HY also receives a honorarium from UpToDate. The remaining authors declare that they have no competing interests.

Clinical Trial

NCT02313272

Funding Statement

The work of this project was initiated at the 2019 Integrated Mathematical Oncology workshop at Moffitt Cancer Center for which the participation of SCB was kindly sponsored by the Moffitt Physical Sciences Oncology Center and the Integrated Mathematical Oncology Department.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All methods were carried out in accordance with relevant guidelines and regulations. The NCT02313272 (05/12/2014) was carried out at the Moffitt Cancer Center, FL between August 2015 and March 2018. All patients provided written consent and the treatment protocol and any of its amendments were approved by the institutional review board of the Moffitt Cancer Center (IRB study \#: Pro00014674 and \# 00000971).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data sets used and/or analysed in the study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: A modelling study based on longitudinal tumor measurements
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: A modelling study based on longitudinal tumor measurements
Sarah C. Brüningk, Jeffrey Peacock, Christopher J. Whelan, Hsiang-Hsuan M. Yu, Solmaz Sahebjam, Heiko Enderling
medRxiv 2021.01.09.21249317; doi: https://doi.org/10.1101/2021.01.09.21249317
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: A modelling study based on longitudinal tumor measurements
Sarah C. Brüningk, Jeffrey Peacock, Christopher J. Whelan, Hsiang-Hsuan M. Yu, Solmaz Sahebjam, Heiko Enderling
medRxiv 2021.01.09.21249317; doi: https://doi.org/10.1101/2021.01.09.21249317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (47)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4857)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (320)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5339)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (780)
  • Public and Global Health (1816)
  • Radiology and Imaging (324)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)